Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of “Moderate Buy” by Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $18.00.

Several equities analysts have weighed in on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Voyager Therapeutics in a research report on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, May 16th. Wedbush dropped their target price on Voyager Therapeutics from $10.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, May 14th. Citigroup assumed coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $16.00 target price for the company. Finally, Guggenheim assumed coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 target price for the company.

Voyager Therapeutics Trading Down 0.6 %

Shares of NASDAQ:VYGR opened at $7.86 on Tuesday. The business has a 50-day moving average price of $8.27 and a 200 day moving average price of $8.40. The company has a market capitalization of $427.51 million, a price-to-earnings ratio of -157.17 and a beta of 0.96. Voyager Therapeutics has a 12-month low of $6.06 and a 12-month high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.24. The firm had revenue of $19.52 million during the quarter, compared to the consensus estimate of $10.33 million. Voyager Therapeutics had a negative return on equity of 1.28% and a negative net margin of 2.56%. As a group, equities research analysts predict that Voyager Therapeutics will post -1.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC purchased a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $1,569,000. Kestra Advisory Services LLC purchased a new stake in Voyager Therapeutics during the third quarter worth approximately $980,000. Ritholtz Wealth Management lifted its stake in Voyager Therapeutics by 11.8% during the fourth quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock worth $167,000 after purchasing an additional 2,089 shares during the last quarter. Alps Advisors Inc. purchased a new stake in Voyager Therapeutics during the third quarter worth approximately $294,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Voyager Therapeutics during the fourth quarter worth approximately $43,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.